Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The future of treating pancreatic exocrine insufficiency

Nature Reviews Gastroenterology & Hepatology volume 23, pages 1–2 (2026)Cite this article

Subjects

Patients with pancreatic exocrine insufficiency are treated with pancreatic enzyme replacement therapy. However, there are several challenges facing the future of this treatment, including infectious agents and the presence of microplastics and nanoplastics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dominguez-Muñoz, J. E. et al. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United Eur. Gastroenterol. J. 13, 125–172 (2025).

    Article  Google Scholar 

  2. Kuhlmann, H. The Magic Potions in the Belly Gland. The Story of Research into the Exocrine Pancreas and the Active Substance Pancreatin (Solvay Pharmaceuticals, 2000).

  3. Gonzalez, J.-P. & Macgregor-Skinner, G. in Zoonoses: Infections Affecting Humans and Animals (ed. Sing, A.) 1563–1611 (Springer, 2023).

  4. Augustyniak, A. & Pomorska-Mól, M. An update in knowledge of pigs as the source of zoonotic pathogens. Animals 13, 3281 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Modesto, P. et al. Evaluation of a molecular method for hepatitis E virus (HEV) detection in pancreatin of porcine origin. J. Virol. Methods 276, 113790 (2020).

    Article  CAS  PubMed  Google Scholar 

  6. Thornton, C. S. et al. Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients. Gut 73, 1702–1711 (2024).

    Article  CAS  PubMed  Google Scholar 

  7. Kamar, N. et al. Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission? Gut 74, 331–332 (2025).

    Article  PubMed  Google Scholar 

  8. Sathe, M., Freedman, S., Gallotto, R., Clarkin, M. & Borowitz, D. 614 Safety of ANG003, a non-porcine pancreatic enzyme replacement therapy in a phase 1 study. J. Cyst. Fibros. 23, S341 (2024).

    Article  Google Scholar 

  9. Brock, A. et al. Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency. Eur. J. Gastroenterol. Hepatol. 28, 1305–1312 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Borowitz, D. et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J. Cyst. Fibros. 10, 443–452 (2011).

    Article  CAS  PubMed  Google Scholar 

  11. Saygin, H. et al. Understanding the PET micro/nanoplastics as an environmental stressor on pancreatin enzyme: leaching and binding characterization by multi-spectroscopic and molecular docking examination, and the resulting impact on Escherichia coli. Nanotoxicology 19, 508–527 (2025).

    Article  CAS  PubMed  Google Scholar 

  12. Mierzejewski, K. et al. PET microplastics increase the risk of insulin resistance and pancreatitis. Preprint at bioRxiv https://doi.org/10.1101/2024.10.25.620380 (2024).

  13. Lebreton, L., Smith, G., Jais, P., Schue, M. & Spoor, T. Reporting a phase II, open-label study assessing the safety and efficacy of MS1819-SD, a recombinant lipase, for the treatment of exocrine pancreatic insufficiency. HPB 21, S173–S174 (2019).

    Article  Google Scholar 

  14. Heubi, J. E. et al. Safety and efficacy of a novel microbial lipase in patients with exocrine pancreatic insufficiency due to cystic fibrosis: a randomized controlled clinical trial. J. Pediatr. 176, 156–161.e1 (2016).

    Article  CAS  PubMed  Google Scholar 

  15. Sathe, M. et al. Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis. J. Cyst. Fibros. https://doi.org/10.1016/j.jcf.2025.07.008 (2025).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Science, Karolinska Institutet, Stockholm, Sweden

    J.-Matthias Löhr

  2. Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden

    J.-Matthias Löhr & Miroslav Vujasinovic

  3. Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Miroslav Vujasinovic

Authors
  1. J.-Matthias Löhr
    View author publications

    Search author on:PubMed Google Scholar

  2. Miroslav Vujasinovic
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to J.-Matthias Löhr.

Ethics declarations

Competing interests

J.-M.L. and M.V. declare lecture honoraria from Abbott, Frostpharma, Nordmark and Viatris.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Löhr, JM., Vujasinovic, M. The future of treating pancreatic exocrine insufficiency. Nat Rev Gastroenterol Hepatol 23, 1–2 (2026). https://doi.org/10.1038/s41575-025-01150-z

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41575-025-01150-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing